Letrozole 5 mg Daily Dosing
Yes, letrozole (Femara) can be prescribed at 5 mg orally once daily for a one-month supply, but this is NOT the FDA-approved dose for breast cancer treatment. The standard FDA-approved dose for breast cancer is 2.5 mg once daily 1, 2.
Context and Appropriate Use
For Breast Cancer (FDA-Approved Indication)
The standard dose is 2.5 mg once daily for:
- Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer
- Extended adjuvant treatment after 5 years of tamoxifen therapy
- First-line and second-line treatment of advanced breast cancer in postmenopausal women 1, 2
Key evidence from major trials:
- MA.17R, NSABP B-42, DATA, IDEAL, and ABCSG 16 trials all used 2.5 mg daily as the standard dose 2
- This dose demonstrated improved disease-free survival and overall survival when used for extended adjuvant therapy
- In the MONALEESA-2 trial, letrozole 2.5 mg combined with ribociclib showed median PFS of 25.3 months versus 16.0 months with letrozole alone 1
For Off-Label Uses (Not FDA-Approved)
Ovulation induction in PCOS:
- 2.5 mg daily for 5 days is the typical starting dose
- 5 mg daily for 5 days has been studied and shows higher pregnancy rates (26.3% vs 5.9%) compared to 2.5 mg 3
- Doses up to 7.5-12.5 mg daily have been used in research settings for resistant cases 4, 5, 6
Ectopic pregnancy (investigational):
- Research protocols have used 5 mg twice daily (10 mg total) for 10 days with 85% resolution rates 7, 8, 9
Critical Safety Considerations
Adverse Effects at Standard Dose (2.5 mg)
From the major adjuvant trials 2:
- Hot flashes (38-54%)
- Arthralgia (50-69%)
- Myalgia (25-37%)
- Fatigue (36-45%)
- Bone fractures: increased risk (14% vs 9% with placebo, p=0.001)
- New osteoporosis: significantly increased (11% vs 6%, p<0.001)
- Cardiovascular events: trend toward increased risk (12% vs 10%)
Important Caveats
There is NO FDA-approved indication for 5 mg daily dosing in breast cancer. Doubling the dose does not improve efficacy for breast cancer treatment and may increase toxicity, particularly:
- Greater bone density loss
- Higher fracture risk
- Increased cardiovascular events
- More severe arthralgias
If prescribing for breast cancer: Use 2.5 mg daily only. The 5 mg dose has not been validated in clinical trials for oncologic indications and offers no demonstrated benefit over standard dosing.
If considering for ovulation induction: This is off-label use. While 5 mg daily for 5 days (not continuous monthly) has research support, this should be prescribed by reproductive endocrinology specialists familiar with the protocols 10, 3, 11.
Monitoring Requirements
For any patient on letrozole:
- Baseline and periodic bone density scans (DEXA)
- Lipid profile monitoring
- Liver function tests
- Consider calcium and vitamin D supplementation
- Cardiovascular risk assessment, especially if QTcF >450 msec when used with CDK4/6 inhibitors 1
Bottom line: For breast cancer, prescribe 2.5 mg daily, not 5 mg. The 5 mg dose lacks evidence for improved outcomes in oncology and increases harm. For fertility indications, 5 mg may be appropriate but only for short courses (5 days), not continuous monthly therapy, and should be managed by specialists.